# An Expanded Access Program of Tarceva (Erlotinib) in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)

> **NCT00949910** · PHASE4 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 6586 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Erlotinib

## Key facts

- **NCT ID:** NCT00949910
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-11
- **Primary completion:** 2009-04
- **Final completion:** 2009-04
- **Target enrollment:** 6586 (ACTUAL)
- **Last updated:** 2016-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00949910

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00949910, "An Expanded Access Program of Tarceva (Erlotinib) in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00949910. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*